Zacks Investment Research cut shares of Bruker Corporation (NASDAQ:BRKR) from a buy rating to a hold rating in a report published on Friday morning.
According to Zacks, “Bruker exited the third quarter on a solid note with better-than-expected earnings and revenue performance. Scientific Instruments segment performed well where growth was driven by strong results within NANO and CALID groups. The company also raised 2017 guidance, which is indicative of brighter prospects. Moving on, the company’s strategic acquisition activity has been encouraging. In this context, the company recently announced the completion of acquisition of Germany-based MERLIN whose products can complement Bruker’s MALDI Biotyper platform. Following its promising third quarter 2017 performance, Bruker has been observed to trade above the broader industry over the past three months. On the flip side, currency fluctuations, competitive landscape and macroeconomic headwinds continue to pose challenges for the company.”
Several other research firms have also weighed in on BRKR. BidaskClub raised Bruker Corporation from a hold rating to a buy rating in a research report on Wednesday, August 16th. Citigroup Inc. boosted their price target on Bruker Corporation from $29.00 to $34.00 and gave the stock a neutral rating in a research report on Friday, November 3rd. Goldman Sachs Group, Inc. (The) reiterated a sell rating and set a $24.00 target price on shares of Bruker Corporation in a research note on Tuesday, September 26th. Barclays PLC reiterated an equal weight rating and set a $30.00 target price (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Finally, J P Morgan Chase & Co upgraded Bruker Corporation from an underweight rating to a neutral rating and set a $28.00 target price for the company in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $29.64.
Bruker Corporation (NASDAQ:BRKR) traded up $0.56 during trading hours on Friday, hitting $32.39. The company’s stock had a trading volume of 657,700 shares, compared to its average volume of 632,791. The firm has a market cap of $5,130.00, a price-to-earnings ratio of 27.20, a price-to-earnings-growth ratio of 2.69 and a beta of 1.05. Bruker Corporation has a 52-week low of $21.03 and a 52-week high of $35.16. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.
Bruker Corporation (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The firm had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker Corporation had a return on equity of 25.83% and a net margin of 8.85%. The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. equities research analysts forecast that Bruker Corporation will post 1.19 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Bruker Corporation (BRKR) Lowered to “Hold” at Zacks Investment Research” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.thestockobserver.com/2017/11/14/bruker-corporation-brkr-lowered-to-hold-at-zacks-investment-research.html.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Investors of record on Monday, December 4th will be paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.49%. Bruker Corporation’s dividend payout ratio (DPR) is presently 17.02%.
In related news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the sale, the vice president now directly owns 60,524 shares in the company, valued at approximately $1,813,904.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 35.20% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC boosted its stake in Bruker Corporation by 496.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 3,185 shares during the period. SG Americas Securities LLC bought a new stake in Bruker Corporation in the 2nd quarter valued at $111,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bruker Corporation by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after purchasing an additional 467 shares during the period. Smithfield Trust Co. bought a new stake in Bruker Corporation in the 2nd quarter valued at $138,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Bruker Corporation by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 331 shares during the period. Institutional investors and hedge funds own 65.47% of the company’s stock.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.